| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 2.05 | 14.9% |
| Total Income | 2.05 | 14.9% |
| Expenditure | 25.19 | 7.3% |
| PBT | — | |
| Net Profit | -20.17 | 6.5% |
| OPM | — | |
| NPM | — | |
| EPS | -0.56 | 6.7% |
BioAge Labs Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 7:47 am
Summary
BioAge Labs reported its third quarter 2025 financial results, highlighting the advancement of BGE-102 into clinical development. Collaboration revenue for the quarter was $2.1 million, driven by the multi-year research collaboration with Novartis. Research and development expenses decreased to $18.5 million, while general and administrative expenses increased to $6.7 million. The net loss for the quarter was $20.2 million, and the company had approximately $295.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
Key Highlights
- 1
BioAge Labs reported collaboration revenue of $2.1 million for the third quarter ended September 30, 2025, compared to no revenue for the same period in 2024.
- 2
Research and development expenses decreased by $1.5 million to $18.5 million for the quarter ended September 30, 2025.
- 3
General and administrative expenses increased by $2.0 million to $6.7 million for the quarter ended September 30, 2025.
- 4
Net loss was $20.2 million for the quarter ended September 30, 2025, compared to a net loss of $23.4 million for the same period in 2024.
- 5
As of September 30, 2025, BioAge had approximately $295.9 million in cash, cash equivalents, and marketable securities.
- 6
The first participant was dosed in a Phase 1 clinical trial evaluating BGE-102 in August 2025, with initial single ascending dose (SAD) data anticipated by the end of 2025.
- 7
The company is advancing oral and parenteral APJ agonist programs targeting IND submissions in 2026.
Management Comments
Kristen Fortney
“The third quarter of 2025 marked an important milestone as we advanced BGE-102 into clinical development with the dosing of our first participant in the Phase 1 trial,” “We're on track to deliver initial single ascending dose data by year-end, providing critical insights into the safety, pharmacokinetics, and target engagement of this potential best-in-class oral, CNS penetrant NLRP3 inhibitor. We also continued to advance our oral and parenteral APJ agonist programs toward 2026 IND submissions, while our partnerships with Novartis and Lilly continue to progress as expected. The Company remains focused on strategic execution to deliver transformative therapies targeting the biology of metabolic aging.”
Informational and educational content only. Not investment advice.